Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;127(5):e1322-5.
doi: 10.1542/peds.2011-0428. Epub 2011 Apr 4.

A systematic review of secretin for children with autism spectrum disorders

Affiliations
Review

A systematic review of secretin for children with autism spectrum disorders

Shanthi Krishnaswami et al. Pediatrics. 2011 May.

Abstract

Context: As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Secretin is 1 of many medical treatments studied for treating the symptoms of ASDs, but there is currently no consensus regarding which interventions are most effective.

Objective: To systematically review evidence regarding the use of secretin in children with ASDs who are aged 12 years and younger.

Methods: We searched the Medline, PsycINFO, and ERIC (Education Resources Information Center) databases from 2000 to May 2010 and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria.

Results: Evidence from 7 randomized controlled trials supports a lack of effectiveness of secretin for the treatment of ASD symptoms including language and communication impairment, symptom severity, and cognitive and social skill deficits. No studies have resulted in significantly greater improvements in measures of language, cognition, or autistic symptoms when compared with placebo; study authors who reported improvement over time did so equally for both the intervention and placebo groups.

Conclusions: Secretin has been studied extensively in multiple randomized controlled trials, and there is clear evidence that it lacks benefit. The studies of secretin included in this review uniformly point to a lack of significant impact of secretin in the treatment of ASD symptoms. Given the high strength of evidence for a lack of effectiveness, secretin as a treatment approach for ASDs warrants no further study.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Location of studies that addressed secretin use in children with ASDs. a The total number of articles in the exclusion categories exceeds the number of articles excluded, because most of the articles fit into multiple exclusion categories.

Comment in

Similar articles

Cited by

References

    1. Tulassay Z, Bodnar A, Farkas I, Papp J, Gupta R. Somatostatin versus secretin in the treatment of actively bleeding gastric erosions. Digestion. 1992;51(4):211–216 - PubMed
    1. Watanabe Y, Tsumura H, Sasaki H. Effect of continuous intravenous infusion of secretin preparation (secrepan) in patients with hemorrhage from chronic peptic ulcer and acute gastric mucosal lesion (AGML). Gastroenterol Jpn. 1991;26(suppl 3):86–89 - PubMed
    1. Charlton CG, Miller RL, Crawley JN, Handelmann GE, O'Donohue TL. Secretin modulation of behavioral and physiological functions in the rat. Peptides. 1983;4(5):739–742 - PubMed
    1. Fremeau RT, Jr, Jensen RT, Charlton CG, Miller RL, O'Donohue TL, Moody TW. Secretin: specific binding to rat brain membranes. J Neurosci. 1983;3(8):1620–1625 - PMC - PubMed
    1. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9(1):9–15 - PubMed